search
Back to results

Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
glimepiride + insulin glargine (Amaryl + Lantus)
glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)
Sponsored by
Handok Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Type 2 Diabetes Mellitus

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients over 20 years old with type 2 DM
  • Patients with inadequate glycemic control despite continuous use of tolerable or maximal doses of one or more OADs for 3months or more.
  • 7%<HbA1c<11 % at screening
  • 21 kg/m2 ≤ BMI ≤ 30 kg/m2
  • Patents who need insulin add-on therapy based on investigator's discretion
  • Patients who would give the informed consent
  • Patients who can perform SMBG and record the data on the patient's diary

Exclusion Criteria:

  • History of acute metabolic complications such as diabetic ketoacidosis or hyperosmolar nonketotic coma within 3 months before screening
  • Pregnant or lactating females
  • History of drug or alcohol abuse
  • Patients with known hypersensitivity to glimepiride, metformin HCL or insulin
  • Night-shift workers
  • Patients who are under insulin therapy at screening
  • Treatment with any investigational products in the last 3 months before screening
  • Clinically significant laboratory abnormality on screening labs or any medical condition that would affect the completion or outcome of the study based on investigator's decision
  • Patients with serum creatinine level > 1.5 mg/dl in male and > 1.4 mg/dl in female
  • Patients with ALT or AST > 3x ULN

Sites / Locations

  • HeeYoung Lee

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Amaryl group

Amaryl M group

Arm Description

Outcomes

Primary Outcome Measures

Mean change in HbA1c from baseline to the last visit

Secondary Outcome Measures

Mean change in FPG, insulin, c-peptide from baseline to the last visit Safety; Episodes of hypoglycemia & other adverse events
Response rate based on HbA1c and FPG levels measured at the last visit
Mean change in Lantus® dose from baseline to the last visit
Compliance
Frequency with hypoglycemic episode
Adverse events

Full Information

First Posted
May 26, 2009
Last Updated
March 26, 2013
Sponsor
Handok Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00913367
Brief Title
Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus
Official Title
A Multi-center, Open, Randomized, Parallel-group, 2 Arm Study to Compare the Efficacy and Safety of Amaryl®M 1/500mg Twice Daily Versus Amaryl® 4mg Both in Combination With Lantus® Once-daily Regimen in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
May 2009 (undefined)
Primary Completion Date
November 2010 (Actual)
Study Completion Date
November 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Handok Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the efficacy of Amaryl®M 1/500 mg twice daily versus Amaryl® 4 mg both in combination with Lantus® once-daily regimen in type 2 Diabetes Mellitus patients with inadequate glycemic control.
Detailed Description
There are several kinds of oral antidiabetic drugs (OADs) that are used in the treatment of patients with type 2 DM. Among them, sulfonylurea and metformin are well-established first-line OADs. However, as the beta cell dysfunction progresses over time, patients fail to achieve good glycemic control with OADs alone and need further treatment intensification, usually involving the introduction of insulin either alone or in combination with OADs. Now, an OAD combined with bedtime insulin is one of the recommended treatment options for patients with type 2 DM and OAD failure. But, it still remains unclear which OADs are the most effective in combination with insulin for the treatment of type 2 DM. so, this study we will be able to verify which OADs are the most effective in combination with insulin for the treatment of type 2 DM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
110 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Amaryl group
Arm Type
Active Comparator
Arm Title
Amaryl M group
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
glimepiride + insulin glargine (Amaryl + Lantus)
Other Intervention Name(s)
Amaryl, Lantus injection solostar
Intervention Description
Amaryl® 4 mg at breakfast + Lantus® at dinner The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast
Intervention Type
Drug
Intervention Name(s)
glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)
Other Intervention Name(s)
Amaryl M, Lantus injection solostar
Intervention Description
Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast
Primary Outcome Measure Information:
Title
Mean change in HbA1c from baseline to the last visit
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Mean change in FPG, insulin, c-peptide from baseline to the last visit Safety; Episodes of hypoglycemia & other adverse events
Time Frame
16 weeks
Title
Response rate based on HbA1c and FPG levels measured at the last visit
Time Frame
16 weeks
Title
Mean change in Lantus® dose from baseline to the last visit
Time Frame
16 weeks
Title
Compliance
Time Frame
16 weeks
Title
Frequency with hypoglycemic episode
Time Frame
16weeks
Title
Adverse events
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients over 20 years old with type 2 DM Patients with inadequate glycemic control despite continuous use of tolerable or maximal doses of one or more OADs for 3months or more. 7%<HbA1c<11 % at screening 21 kg/m2 ≤ BMI ≤ 30 kg/m2 Patents who need insulin add-on therapy based on investigator's discretion Patients who would give the informed consent Patients who can perform SMBG and record the data on the patient's diary Exclusion Criteria: History of acute metabolic complications such as diabetic ketoacidosis or hyperosmolar nonketotic coma within 3 months before screening Pregnant or lactating females History of drug or alcohol abuse Patients with known hypersensitivity to glimepiride, metformin HCL or insulin Night-shift workers Patients who are under insulin therapy at screening Treatment with any investigational products in the last 3 months before screening Clinically significant laboratory abnormality on screening labs or any medical condition that would affect the completion or outcome of the study based on investigator's decision Patients with serum creatinine level > 1.5 mg/dl in male and > 1.4 mg/dl in female Patients with ALT or AST > 3x ULN
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kang S Park
Organizational Affiliation
Eulji University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
HeeYoung Lee
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs